
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

T-MAXIMUM's Allogeneic CAR-T MT027 Gets FDA IND for Glioblastoma Phase II
Details : MT027, a Cell & Gene Therapy targeting CD276, shows promise in treating Recurrent Glioblastoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 21, 2025
